http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Article/list/9396 Treatment and research news and developments about bladder cancer, kidney cancer, testicular cancer, penile cancer, and other urologic cancers. 2009-11-21T08:12:44Z http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Repeat-resection-emphasized-in-new-bladder-cancer-/ArticleStandard/Article/detail/489172?contextCategoryId=9396&ref=25 Among the many recommendations within the new AUA guideline for the management of nonmuscle-invasive bladder cancer, arguably one of the most important is the idea of repeating resection for patients with high-grade Ta or T1 disease within a few weeks of the initial resection before making a treatment recommendation. 2008-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/062008/489172null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/New-chemotherapeutic-approaches-in-superficial-bla/ArticleStandard/Article/detail/636486?contextCategoryId=9396&ref=25 An overview of new agents and device-assisted therapies being investigated to improve outcomes for patients with superficial bladder cancer. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/636486null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Bladder-augmentation-What-the-future-holds/ArticleStandard/Article/detail/636347?contextCategoryId=9396&ref=25 This article reviews current developments in cellular scaffods, the process of cell seeding, and the importance of a favorable in vitro environment for regeneration. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/432009/636347null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Study-Marijuana-use-testicular-cancer-may-be-linke/ArticleStandard/Article/detail/591119?contextCategoryId=9396&ref=25 Results of a population-based, case-control study suggest there may be an association between marijuana use and the occurrence of testicular germ cell tumors (TGCTs), researchers from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, reported. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591119null XML http://urologytimes.modernmedicine.com/urologytimes/Kidney+%26+Bladder+Cancer+Top+Story/Tumor-factors-only-partly-explain-bladder-cancer-d/ArticleStandard/Article/detail/591101?contextCategoryId=9396&ref=25 In patients with bladder cancer, tumor characteristics at presentation are less favorable in women and African-Americans versus Caucasian men, according to a study by researchers at the University of Rochester, New York. 2009-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/142009/591101null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Treating-renal-cell-carcinoma-Cryoablation-or-part/ArticleStandard/Article/detail/573151?contextCategoryId=9396&ref=25 In the treatment of renal cell carcinoma, partial nephrectomy produces better quality of life than cryoablation, according to researchers at Washington University, St. Louis. 2009-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522008/573151null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Treatment-of-small-renal-masses-Quality-or-quantit/ArticleStandard/Article/detail/573135?contextCategoryId=9396&ref=25 The practicing urologist faces an increasingly common dilemma: How should I treat this incidentally discovered small renal mass? 2009-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522008/573135null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Data-may-squelch-concerns-over-statins-effects-on-/ArticleStandard/Article/detail/573137?contextCategoryId=9396&ref=25 Statin drugs appear to have no effect on intravesical bacillus Calmette-Guerin (BCG) treatment outcomes in patients with non-muscle invasive bladder cancer, according to a recent retrospective study among Veterans Affairs patients in St. Louis. 2009-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522008/573137null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Robotic-cystectomy-shows-favorable-oncologic-outco/ArticleStandard/Article/detail/573139?contextCategoryId=9396&ref=25 Based on new mid-term study results, robot-assisted laparoscopic cystectomy appears to be slowly moving toward mainstream surgical practice. 2009-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522008/573139null XML http://www.modernmedicine.com/modernmedicine/Kidney+%26+Bladder+Cancer+Top+Story/Adjuvant-chemotherapy-essential-to-bladder-cancer-/ArticleStandard/Article/detail/563889?contextCategoryId=9396&ref=25 Adjuvant chemotherapy is an essential part of the treatment protocol for lymph node-positive bladder cancer. 2008-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452008/563889null XML http://www.modernmedicine.com/modernmedicine/Surgery/Patience-required-when-evaluating-radiofrequency-a/ArticleStandard/Article/detail/557220?contextCategoryId=9396&ref=25 Evaluating the efficacy of radiofrequency ablation of renal cortical tumors requires a degree of patience because histologic changes and cell death in and near lesions targeted by the treatment may continue to evolve for a year or even longer. 2008-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/412008/557220null XML http://urologytimes.modernmedicine.com/urologytimes/News/Once-daily-RCC-therapy-granted-priority-review/ArticleStandard/Article/detail/552232?contextCategoryId=9396&ref=25 Novartis has announced that RAD001 (everolimus), an oral once-daily inhibitor of mTOR, for treatment of advanced kidney cancer, has been granted priority review by the FDA. 2008-09-25T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392008/552232null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Patients-unaware-of-link-between-smoking-bladder-c/ArticleStandard/Article/detail/548458?contextCategoryId=9396&ref=25 Although cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection, including more than three-quarters of patients who have the disease, according to a new study from the University of Michigan Comprehensive Cancer Center, Ann Arbor. This knowledge vacuum suggests that urologists need to communicate the risks of smoking to their patients and encourage them to quit, study authors say. 2008-09-11T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548458null HTML http://www.modernmedicine.com/modernmedicine/Kidney+%26+Bladder+Cancer/Prostate-cancer-radiotherapy-raises-bladder-rectal/ArticleStandard/Article/detail/548549?contextCategoryId=9396&ref=25 Men who receive some form of radiotherapy for localized prostate cancer have an elevated risk of later developing bladder and rectal cancers. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548549null XML http://www.modernmedicine.com/modernmedicine/Urology/Data-on-second-line-bladder-cancer-treatments-leav/ArticleStandard/Article/detail/543671?contextCategoryId=9396&ref=25 Results of a phase three study evaluating second-line chemotherapy with gemcitabine/paclitaxel for metastatic bladder cancer failed to answer its primary question of whether maintenance treatment is superior to a temporary six-cycle regimen because maintenance treatment was usually not possible. However specific subgroups of patients who may be more likely to benefit from this combination regimen after failing first-line chemotherapy. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543671null XML http://www.modernmedicine.com/modernmedicine/Urology/Cystectomy-still-best-option-when-bacillus-Calmett/ArticleStandard/Article/detail/543651?contextCategoryId=9396&ref=25 Bacillus Calmette-Guerin remains the treatment of choice for bladder cancer in the United States, but more than half of patients with nonmuscle-invasive bladder cancers will eventually fail BCG. Several promising alternative treatments are under development, but radical cystectomy remains the optimal choice for patients who fail BCG. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543651null XML http://www.modernmedicine.com/modernmedicine/Urology/Testis-cancer-Cognitive-decline-is-possible-risk-o/ArticleStandard/Article/detail/543650?contextCategoryId=9396&ref=25 Findings from a study of testicular cancer survivors add to existing evidence that cognitive impairment is a potential long-term risk of cancer chemotherapy. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543650null XML http://www.modernmedicine.com/modernmedicine/Urology/Bisphosphonate-shows-benefits-in-bladder-cancer/ArticleStandard/Article/detail/543649?contextCategoryId=9396&ref=25 The bisphosphonate zoledronic acid (Zometa) offers significant benefit in lowering the skeletal-related events rate in patients with bony metastatic bladder cancer, according to results of a prospective, randomized, placebo-controlled study. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543649null XML http://www.modernmedicine.com/modernmedicine/Urology/Renal-cell-carcinoma-combination-therapies-Some-go/ArticleStandard/Article/detail/543652?contextCategoryId=9396&ref=25 Combination therapy using targeted agents is a promising yet elusive target in renal cell carcinoma, but questions about toxicity and benefits versus monotherapy have been raised in other studies. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543652null XML http://www.modernmedicine.com/modernmedicine/Urology/Palliative-nephrectomy-beneficial-in-advanced-rena/ArticleStandard/Article/detail/543673?contextCategoryId=9396&ref=25 Long-term results from Southwest Oncology Group trial S8949 confirm the original study finding that performing palliative debulking surgery prior to starting systemic therapy with interferon alfa-2b confers a survival benefit in patients with advanced renal cell carcinoma. 2008-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342008/543673null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Heart-failure-associated-with-RCC-treatment/ArticleStandard/Article/detail/529334?contextCategoryId=9396&ref=25 Sunitinib malate (Sutent), indicated for the treatment of metastatic renal cell carcinoma, may be associated with heart failure in less than 3% of patients receiving the drug, according to a study published in Cancer (2008; 112:2500-8). The finding may represent a potentially serious toxicity and may underscore the need for careful monitoring of cardiac function and aggressive control of hypertension in these patients. 2008-07-17T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/292008/529334null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Adjuvant-chemotherapy-after-cystectomy-may-prolong/ArticleStandard/Article/detail/518205?contextCategoryId=9396&ref=25 A retrospective study of patients seen at the University of Chicago suggests that adjuvant chemotherapy is an essential part of the treatment protocol for lymph node-positive bladder cancer. 2008-05-20T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/212008/518205null HTML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/When-is-immediate-cystectomy-necessary-in-TCC/ArticleStandard/Article/detail/517406?contextCategoryId=9396&ref=25 While immediate cystectomy offers excellent long-term outcomes for patients with high-grade T1 transitional cell carcinoma, genetic biomarkers one day could help urologists select the most appropriate candidates for this surgery. 2008-05-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/202008/517406null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Pesticide-exposure-may-increase-testicular-tumor-r/ArticleStandard/Article/detail/514996?contextCategoryId=9396&ref=25 Exposure to endocrine-disrupting chemicals, such as persistent organochlorine pesticides, is associated with the risk of both seminomatous and nonseminomatous testicular germ cell tumors, whereas exposure to chlordane compounds and metabolites may be associated with the risk of seminoma, according to a study published in an online issue of the Journal of the National Cancer Institute (April 28). 2008-05-08T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/514996null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Cancer-survivors-have-low-levels-of-physical-activ/ArticleStandard/Article/detail/514992?contextCategoryId=9396&ref=25 A new study reveals that many cancer survivors are inactive and obese, which may negatively affect the control of their disease. The findings, which come from a study of cancer survivors in Canada, show that a cancer diagnosis does not appear to prompt significant behavior change and that interventions to increase physical activity and promote better eating habits among cancer survivors are warranted. 2008-05-08T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/514992null HTML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Laparoscopic-renal-surgery-Ongoing-progress-promis/ArticleStandard/Article/detail/515197?contextCategoryId=9396&ref=25 Since the initial description of laparoscopic nephrectomy by Clayman and associates in 1991, the technique and the principles of the procedure have evolved logically. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515197null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Data-dispute-en-bloc-ligation-arteriovenous-fistul/ArticleStandard/Article/detail/515192?contextCategoryId=9396&ref=25 Researchers now have evidence that the risk of arteriovenous fistula formation is low in patients who undergo en bloc ligation. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515192null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Radiofrequency-device-may-help-minimize-bleeding-d/ArticleStandard/Article/detail/515233?contextCategoryId=9396&ref=25 Researchers have developed a novel technique of performing laparoscopic partial nephrectomy without renal hilar clamping that appears to minimize blood loss during the procedure. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515233null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Laparoscopic-nephrectomy-Not-just-for-localized-re/ArticleStandard/Article/detail/515193?contextCategoryId=9396&ref=25 Intermediate-term oncologic results after laparoscopic radical nephrectomy for locally advanced renal cell carcinoma are similar to those of open nephrectomy. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515193null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Endoscopy-Safe-option-in-select-upper-tract-transi/ArticleStandard/Article/detail/515198?contextCategoryId=9396&ref=25 With continuing advances in endoscopic equipment combined with the increasing dissemination of ureteroscopic skills, upper tract TCC is increasingly being evaluated and treated endoscopically. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515198null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Patients-with-pelvic-recurrence-post-cystectomy-ha/ArticleStandard/Article/detail/511630?contextCategoryId=9396&ref=25 Patients with pelvic recurrence after radical cystectomy for transitional cell carcinoma have a poor prognosis, even with subsequent therapy, emphasizing the need for optimum local control at the time of initial treatment, according to a study published in The British Journal of Urology International (2008; 101:969–72). 2008-04-24T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/172008/511630null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Study-offers-hope-for-children-with-kidney-tumors/ArticleStandard/Article/detail/508484?contextCategoryId=9396&ref=25 Children with bilateral Wilms’ tumors can retain normal function in both kidneys by undergoing bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable, report researchers at St. Jude Children’s Research Hospital, Memphis, TN. 2008-04-10T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/152008/508484null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Testicular-cancer-gauge-often-underused/ArticleStandard/Article/detail/505276?contextCategoryId=9396&ref=25 Serum-based tumor markers are not used in more than half of all patients who have testis cancer, report researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor. 2008-03-27T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/132008/505276null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/First-line-bladder-cancer-therapy-receives-fast-tr/ArticleStandard/Article/detail/502125?contextCategoryId=9396&ref=25 The FDA has indicated that a new therapy for first-line nonmuscle-invasive bladder cancer meets the criteria for fast track designation. 2008-03-13T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112008/502125null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Targeted-therapy-extends-progression-free-survival/ArticleStandard/Article/detail/502121?contextCategoryId=9396&ref=25 An independent data monitoring committee stopped a major phase III clinical trial of the investigational drug everolimus (RAD001) after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared with placebo. 2008-03-13T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112008/502121null HTML http://www.modernmedicine.com/modernmedicine/Male+Infertility/Male-factor-infertility-testicular-cancer-linked/ArticleStandard/Article/detail/498997?contextCategoryId=9396&ref=25 Men with a history of infertility have a markedly increased risk of subsequently developing testicular cancer. 2008-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/092008/498997null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Cystectomy-over-age-80-Patient-selection-is-key/ArticleStandard/Article/detail/498999?contextCategoryId=9396&ref=25 For very elderly patients with bladder cancer, good outcomes with radical cystectomy are possible primarily through appropriate patient selection, timely surgical management, and meticulous postoperative care. 2008-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/092008/498999null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Advances-in-kidney-cancer-therapy/ArticleStandard/Article/detail/501586?contextCategoryId=9396&ref=25 Traditional immunotherapy for renal cell carcinoma (RCC) is being supplanted by new medications that target the biology of kidney cancer. Based on demonstrated efficacy, 3 of these novel agents have now been approved for advanced disease. 2008-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112008/501586null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/New-stem-cell-sources-offer-hope-for-wider-clinica/ArticleStandard/Article/detail/498998?contextCategoryId=9396&ref=25 Research led by Anthony Atala, MD, has shown that non-embryonic sources of stem cells may lead to safer, more effective clinical use. 2008-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/092008/498998null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Renal-cancer-drugs-may-be-linked-to-hypertension-o/ArticleStandard/Article/detail/491172?contextCategoryId=9396&ref=25 Two newer drugs used for the treatment of advanced renal cell carcinoma may be associated with an elevated risk of hypertension and other cardiovascular side effects, according to results of two separate studies. 2008-02-14T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/072008/491172null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Novel-laparoscopic-partial-nephrectomy-technique-a/ArticleStandard/Article/detail/489186?contextCategoryId=9396&ref=25 Use of hemostatic hydrodissection and bipolar vessel coagulation appears to be a viable method for avoiding vascular clamping and subsequent renal ischemia while performing laparoscopic or robotic partial nephrectomy. 2008-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/062008/489186null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Testicular-pain-common-after-laparoscopic-nephrect/ArticleStandard/Article/detail/489185?contextCategoryId=9396&ref=25 Men undergoing laparoscopic nephrectomy should be warned that they might develop testicular pain postoperatively. 2008-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/062008/489185null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Diagnostics-firm-finalizes-Matritech-acquisition/ArticleStandard/Article/detail/486694?contextCategoryId=9396&ref=25 Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test. 2008-01-31T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/042008/486694null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Developer-of-bladder-cancer-drug-receives-non-appr/ArticleStandard/Article/detail/482804?contextCategoryId=9396&ref=25 Indevus Pharmaceuticals, Inc. has received a non-approvable letter from FDA for valrubicin for intravesical instillation (Valstar), related to the drug’s chemistry, manufacturing, and controls new drug application supplement submitted to the FDA last May. Valrubicin is indicated for bacillus Calmette-Guerin-refractory carcinoma in situ of the bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. 2008-01-10T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/022008/482804null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Drug-combination-shows-significant-survival-advant/ArticleStandard/Article/detail/482675?contextCategoryId=9396&ref=25 The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11). 2008-01-10T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/022008/482675null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Nonmuscle-invasive-bladder-cancer-Treating-initial/ArticleStandard/Article/detail/482235?contextCategoryId=9396&ref=25 This article guides the clinician in the management of initial and recurrent nonmuscle-invasive bladder cancer. 2008-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/022008/482235null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Broccoli-other-cruciferous-vegetables-may-help-pre/ArticleStandard/Article/detail/480223?contextCategoryId=9396&ref=25 Researchers at Roswell Park Cancer Institute in Buffalo, NY, have found that broccoli sprouts, a rich source of isothiocyanates, may play a direct role in preventing bladder cancer. 2007-12-20T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/512007/480223null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/AUA-releases-new-guidelines-on-bladder-cancer-uret/ArticleStandard/Article/detail/477266?contextCategoryId=9396&ref=25 AUA has announced the release of new guidelines on the management of two common urologic conditions: nonmuscle-invasive bladder cancer and ureteral calculi. 2007-12-06T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492007/477266null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Renal-cryoablation-shows-positive-results-at-up-to/ArticleStandard/Article/detail/477271?contextCategoryId=9396&ref=25 Patients who undergo cryoablation to treat cancerous kidney tumors are cancer free for up to 2.5 years after having the procedure, according to a study conducted by researchers from the Mayo Clinic, Rochester, MN. 2007-12-06T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492007/477271null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Sword-fire-ice-offer-options-in-small-renal-masses/ArticleStandard/Article/detail/475202?contextCategoryId=9396&ref=25 Nephron-sparing procedures now have clear advantages over radical nephrectomy for most small renal masses. 2007-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/482007/475202null XML http://urologytimes.modernmedicine.com/urologytimes/Prostate+Cancer/CMS-sets-reimbursement-rates-for-prostate-renal-cr/ArticleStandard/Article/detail/472505?contextCategoryId=9396&ref=25 The Centers for Medicare & Medicaid Services has increased hospital outpatient and ambulatory surgical center reimbursement rates for cryoablation treatments for prostate cancer, and has created a reimbursement code and rate for percutaneous renal cryoablation. The new rates will go into effect in 2008. 2007-11-15T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/462007/472505null HTML http://www.modernmedicine.com/modernmedicine/In+the+OR/Hand-assisted-donor-nephrectomy-presents-challenge/ArticleStandard/Article/detail/465158?contextCategoryId=9396&ref=25 Patient factors, level of surgeon training, and certain surgical steps appear to represent impediments to learning hand-assisted laparoscopic donor nephrectomy (HALDN). 2007-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422007/465158null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Glycoprotein-is-potential-bladder-cancer-marker/ArticleStandard/Article/detail/465159?contextCategoryId=9396&ref=25 A team of German researchers is pursuing promising research on oncofetal fibronectin as a potential marker for bladder cancer. 2007-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422007/465159null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Adjuvant-therapy-may-benefit-subsets-of-renal-cell/ArticleStandard/Article/detail/460663?contextCategoryId=9396&ref=25 Adjuvant immunotherapy with interleukin-2 (IL-2) plus interferon-alpha offers no survival advantage to the overall population of patients with resected renal cell carcinoma, but may benefit selected subgroups of patients. 2007-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392007/460663null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Technique-role-of-extended-lymphadenectomy-in-blad/ArticleStandard/Article/detail/460666?contextCategoryId=9396&ref=25 Lymphadenectomy in conjunction with radical cystectomy (RC) is the standard approach for surgical management of high-grade, invasive bladder cancer. Approximately 25% of patients undergoing RC will be found to have lymph node-positive disease. 2007-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392007/460666null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Staging-system-for-renal-cell-carcinoma-is-reliabl/ArticleStandard/Article/detail/460665?contextCategoryId=9396&ref=25 A staging system that accounts for interactions among tumor stage and grade and patient performance status offers a reliable and reproducible means for predicting mortality after surgery for renal cell carcinoma. 2007-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392007/460665null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/VEGF-inhibitors-show-survival-advantages-in-renal-/ArticleStandard/Article/detail/460662?contextCategoryId=9396&ref=25 Survival advantages in metastatic renal cell carcinoma have emerged from clinical trials of two different vascular endothelial growth factor (VEGF) inhibitors. 2007-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392007/460662null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/VEGF-levels-may-predict-survival-in-renal-cell-car/ArticleStandard/Article/detail/460664?contextCategoryId=9396&ref=25 In patients with metastatic renal cell carcinoma, baseline levels of vascular endothelial growth factor (VEGF) predicted overall and progression-free survival, providing additional support for therapies that target VEGF. 2007-10-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/392007/460664null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Company-slated-to-re-introduce-bladder-cancer-drug/ArticleStandard/Article/detail/458047?contextCategoryId=9396&ref=25 Indevus Pharmaceuticals, Inc. has received an approvable letter from the FDA for valrubicin (Valstar), indicated for intravesical therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ of the bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. 2007-09-20T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/382007/458047null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Urologists-use-single-keyhole-surgery-to-remove-ki/ArticleStandard/Article/detail/453773?contextCategoryId=9396&ref=25 Surgeons at the University of Texas Southwestern Medical Center, Dallas, effectively removed a patient's kidney by conducting an atypical nephrectomy, known as “single keyhole access” surgery, via the umbilicus. This marked the first such surgery that involved a kidney, and it required one incision. 2007-09-06T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/352007/453773null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/NCCN-updates-kidney-cancer-guidelines-to-include-n/ArticleStandard/Article/detail/449642?contextCategoryId=9396&ref=25 The National Comprehensive Cancer Network has made updates to its kidney cancer guidelines to include the addition of two first-line treatment options. 2007-08-17T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/332007/449642null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Family-history-is-significant-in-kidney-cancer-ris/ArticleStandard/Article/detail/444487?contextCategoryId=9396&ref=25 Based on the relative risk to siblings, 80% of kidney cancer cases are likely to occur in 20% of the population with the highest genetic risk, indicating the importance of further investigation of genetic factors in cancer prevention, according to a European multicenter, case-control study. 2007-08-02T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444487null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Study-supports-early-cystectomy-for-pT1G3-TCC/ArticleStandard/Article/detail/444362?contextCategoryId=9396&ref=25 It may be time to update treatment guidelines for transitional cell carcinoma. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444362null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Study-documents-features-outcomes-of-upper-tract-T/ArticleStandard/Article/detail/444365?contextCategoryId=9396&ref=25 The primary message from a study evaluating long-term urothelial recurrence and disease-specific survival after radical nephroureterectomy for upper tract transitional cell carcinoma is that there remains a critical need for better methods to enable early diagnosis. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444365null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Adjuvant-BCG-offers-no-benefit-in-upper-tract-TCC/ArticleStandard/Article/detail/444355?contextCategoryId=9396&ref=25 Adjuvant bacillus Calmette-Guerin appears to provide no benefit for improving the oncologic outcome of patients with upper tract transitional cell carcinoma undergoing nephroureterectomy. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444355null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Outcomes-favor-extended-PLND-in-radical-cystectomy/ArticleStandard/Article/detail/444366?contextCategoryId=9396&ref=25 Results of a retrospective, inter-institutional study comparing outcomes of patients with urothelial carcinoma of the bladder highly favor the use of an extended template for bilateral pelvic lymph node dissection (PLND) when performing radical cystectomy. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444366null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Factors-predicting-bladder-TCC-survival-identified/ArticleStandard/Article/detail/444354?contextCategoryId=9396&ref=25 A multi-institutional retrospective analysis has identified five variables that independently predict cancer-specific survival in patients with nonmetastatic transitional cell carcinoma of the upper urinary tract. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444354null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Two-step-TURB-improves-superficial-TCC-outcomes/ArticleStandard/Article/detail/444363?contextCategoryId=9396&ref=25 A two-step transurethral resection (TURB) procedure in patients with superficial transitional bladder cancer, already part of practice guidelines in Germany, appears to improve patient outcomes by identifying positive tumor beds that may require a second TURB. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444363null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Endoscopy-may-be-effective-in-select-TCC-patients/ArticleStandard/Article/detail/444364?contextCategoryId=9396&ref=25 Patients with a relatively small volume of low-grade upper tract transitional cell carcinoma can be managed by purely endoscopic means over a long period of time. 2007-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/302007/444364null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Bladder-cancer-deaths-continue-decades-after-arsen/ArticleStandard/Article/detail/438846?contextCategoryId=9396&ref=25 Arsenic exposure appears to continue causing bladder and lung cancer deaths years after exposure ends, according to a study published in the Journal of the National Cancer Institute (2007; 99:905). 2007-07-05T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/272007/438846null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/ACS-launches-major-study-of-genetic-environmental-/ArticleStandard/Article/detail/436578?contextCategoryId=9396&ref=25 The American Cancer Society has opened enrollment for a large-scale population-based study focused on cancer and its genetic and environmental connections. 2007-06-21T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/252007/436578null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/FDA-approves-third-new-targeted-therapy-for-advanc/ArticleStandard/Article/detail/431790?contextCategoryId=9396&ref=25 The FDA has approved the enzyme inhibitor temsirolimus (Torisel) for the treatment of advanced renal cell carcinoma. 2007-06-07T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431790null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Metastasectomy-for-RCC-Rationale-and-outcomes/ArticleStandard/Article/detail/431397?contextCategoryId=9396&ref=25 This article centers around the rationale and outcomes of the converse issue; namely, removal of metastatic extrarenal foci of RCC. 2007-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431397null XML http://urologytimes.modernmedicine.com/urologytimes/Urology/Cryoablation-preferred-to-RF-in-small-renal-masses/ArticleStandard/Article/detail/427789?contextCategoryId=9396&ref=25 The use of cryoablation, rather than radiofrequency (RF) ablation for the treatment of small renal masses may be controversial for some urologists, but recent data support the superiority of cryoablation. 2007-05-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/202007/427789null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Androgen-receptor-plays-role-in-bladder-cancer-dev/ArticleStandard/Article/detail/423941?contextCategoryId=9396&ref=25 The androgen receptor appears to play a key role in the development of bladder cancer, revealing why the disease is more prevalent in men than in women, according to a study published in the Journal of the National Cancer Institute (2007; 99:558-68). This finding could open the door to new types of treatment. 2007-05-03T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182007/423941null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Research-collaborative-formed-to-explore-biomarker/ArticleStandard/Article/detail/423943?contextCategoryId=9396&ref=25 The American Association for Cancer Research (AACR) has announced the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative to facilitate the use of validated biomarkers in clinical trials and, ultimately, their use in evidence-based oncology and cancer medicine. The collaborative includes researchers from academia, government, and industry, as well as patient advocacy groups. 2007-05-03T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182007/423943null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/RCC-Urologists-role-in-the-targeted-therapy-era/ArticleStandard/Article/detail/423967?contextCategoryId=9396&ref=25 The treatment of metastatic renal cell carcinoma has undergone significant changes. 2007-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182007/423967null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Testicular-cancer-survivors-at-risk-of-dying-from-/ArticleStandard/Article/detail/420298?contextCategoryId=9396&ref=25 Men who have survived for at least 1 year after being diagnosed with testicular cancer have a slightly higher risk of dying from non-cancer causes—including infections, digestive diseases, and circulatory diseases—than the general population does, a study published in the Journal of the National Cancer Institute (2007; 99:533-44) suggests. Men treated with chemotherapy in 1975 or later may be at particularly high risk. 2007-04-19T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/162007/420298null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Biomarker-changes-may-predict-bladder-cancer-outco/ArticleStandard/Article/detail/420449?contextCategoryId=9396&ref=25 Assessment of a set of four apoptosis markers in patients with urothelial-cell carcinoma of the bladder appears helpful for predicting which patients are at elevated risk for disease recurrence and disease-specific mortality after radical cystectomy and bilateral lymphadenectomy. 2007-04-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/162007/420449null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Antibodyrsquos-actions-may-attack-tumorsrsquo-bloo/ArticleStandard/Article/detail/411599?contextCategoryId=9396&ref=25 An antibody known as J591 may precisely target the blood supply of various urologic and other tumors while avoiding healthy tissues, according to research from New York-Presbyterian Hospital/Weill Cornell Medical Center, New York. 2007-03-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112007/411599null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Cryo-may-be-as-effective-as-laparoscopic-removal-f/ArticleStandard/Article/detail/411603?contextCategoryId=9396&ref=25 Percutaneous cryoablation of kidney tumors may be as effective as laparoscopy in eligible patients, according to research presented at the Society of Interventional Radiology’s 32nd annual scientific meeting in Seattle. 2007-03-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/112007/411603null HTML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Oral-kinase-inhibitors-assume-new-roles-in-RCC/ArticleStandard/Article/detail/408856?contextCategoryId=9396&ref=25 New York—Management of metastatic, clear-cell renal cell carcinoma has been significantly advanced by the development of the oral small-molecule kinase inhibitors sunitinib malate (Sutent) and sorafenib (Nexavar), recent results from two large, international, randomized, double-blind, phase III trials indicate. Both studies appeared in the Jan. 11, 2007 issue of the New England Journal of Medicine (2007; 356:115-24 and 125-34). 2007-03-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/102007/408856null XML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Biomarker-test-could-predict-outcome-for-bladder-c/ArticleStandard/Article/detail/404644?contextCategoryId=9396&ref=25 A set of molecular biomarkers might predict the recurrence of bladder cancer and survival from the disease better than conventional prognostic features, University of Texas Southwestern Medical Center, Dallas, researchers have found. Once a patient undergoes radical cystectomy, researchers say a routine tissue analysis could easily test for the presence of altered proteins that they found to help ascertain the chances that the cancer will return. 2007-02-15T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/072007/404644null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/FDA-approves-new-labeling-for-advanced-RCC-treatme/ArticleStandard/Article/detail/404638?contextCategoryId=9396&ref=25 The FDA has approved new labeling for sunitinib malate (Sutent) to include first-line treatment of advanced renal cell carcinoma. The labeling change is based on results of a large phase III trial that showed prolonged progression-free survival. 2007-02-15T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/072007/404638null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Automated-bladder-cancer-test-receives-FDA-clearan/ArticleStandard/Article/detail/401244?contextCategoryId=9396&ref=25 Ikonisys Inc. has received FDA approval to market the oncoFISH bladder diagnostic application in the United States. In conjunction with the company’s proprietary Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer. 2007-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052007/401244null HTML http://urologytimes.modernmedicine.com/urologytimes/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/New-drugs-increase-progression-free-survival-in-ad/ArticleStandard/Article/detail/398391?contextCategoryId=9396&ref=25 Two new drugs for advanced renal cell carcinoma effectively increase progression-free survival in patients with the disease, according to separate studies published last week in the New England Journal of Medicine (2007; 356:125-34; and 115-24). 2007-01-18T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/032007/398391null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Combination-therapy-improves-progression-free-surv/ArticleStandard/Article/detail/395477?contextCategoryId=9396&ref=25 Bevacizumab (Avastin) in combination with interferon alfa-2a (Roferon-A) therapy in patients with first-line metastatic renal cell carcinoma appears to significantly improve progression-free survival compared with interferon alfa-2a therapy alone, according to recent findings from an unpublished interim analysis of phase III data. 2007-01-04T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/012007/395477null HTML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Watchful-waiting-is-possible-option-for-renal-mass/ArticleStandard/Article/detail/395034?contextCategoryId=9396&ref=25 Chicago—In patients with a contrast-enhancing renal mass, delayed intervention after watchful waiting does not adversely affect pathologic outcomes, results of a retrospective study designed to gain insight into the natural history of "incidentalomas" indicate. This holds true even for some lesions that are relatively large at diagnosis or found on follow-up to be rapidly growing, researchers from University of North Carolina at Chapel Hill reported at the American College of Surgeons clinical congress. 2007-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522006/395034null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Morcellation-may-worsen-staging-of-renal-tumors/ArticleStandard/Article/detail/390262?contextCategoryId=9396&ref=25 Cleveland—Understaging of renal tumors on the basis of clinical criteria appears problematic when tumors are morcellated during laparoscopic nephrectomy, according to a Mayo Clinic study presented at the 2006 World Congress of Endourology here. 2006-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492006/390262null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Controversy-practical-issues-shape-TCC-grading/ArticleStandard/Article/detail/390266?contextCategoryId=9396&ref=25 Beginning in 1998, consensus conferences concerning the grading of urothelial cancer addressed removal of the word "carcinoma" from low-grade papillary tumors with little or no malignant potential. The subsequent change in terminology has been controversial, however, and many pathologists as well as most urologists continue to use the traditional three-grade classification system. 2006-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492006/390266null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Open-versus-lap-nephrectomy-Similar-long-term-outc/ArticleStandard/Article/detail/390265?contextCategoryId=9396&ref=25 Cleveland—Which approach to radical nephrectomy produces the most durable outcomes in survival and restored renal function: laparoscopy or open surgery? 2006-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492006/390265null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Program-offers-free-bladder-cancer-screening-for-f/ArticleStandard/Article/detail/383366?contextCategoryId=9396&ref=25 Firefighters in five Rhode Island communities are being offered free screening for bladder cancer in a voluntary program paid for and sponsored by their local state representatives. 2006-11-02T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442006/383366null HTML http://www.modernmedicine.com/modernmedicine/News/Lower-renal-cancer-risk-linked-to-sunlight-fatty-f/ArticleStandard/Article/detail/384318?contextCategoryId=9396&ref=25 San Diego, CA—Exposure to ultraviolet B (UVB) irradiation through natural sunlight and dietary intake of fatty fish are independent predictors of renal cancer risk, according to the findings of two recently published studies. 2006-11-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452006/384318null XML http://www.modernmedicine.com/modernmedicine/News/RCC-disconnect-Both-treatment-mortality-rising/ArticleStandard/Article/detail/384320?contextCategoryId=9396&ref=25 Ann Arbor, MI—Results of a study from the University of Michigan here provide further evidence that the incidence of kidney cancer and the rate of surgical treatment are both on the rise. However, those trends are primarily accounted for by the identification and management of small, presumably curable renal masses (?4 cm). Meanwhile, mortality rates in kidney cancer patients have also been increasing, driven by worsening outcomes of patients with the largest tumors (>7 cm). 2006-11-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452006/384320null XML http://www.modernmedicine.com/modernmedicine/News/Council-warns-of-strong-ties-between-TCE-kidney-ca/ArticleStandard/Article/detail/384319?contextCategoryId=9396&ref=25 Washington—Trichloroethylene (TCE) is a chlorinated hydrocarbon once commonly used as a degreasing agent in industrial settings. The nonflammable, colorless fluid may also be found as an ingredient in adhesives, paint removers, typewriter correction fluids, and spot removers. Although a clear-cut link between TCE and cancer has yet to be established, the chemical is the subject of a recent report calling for research on how it causes cancer and other adverse health effects. 2006-11-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452006/384319null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Cryotherapy-for-renal-tumors-shows-46-failure-rate/ArticleStandard/Article/detail/381348?contextCategoryId=9396&ref=25 Cleveland—The news regarding laparoscopic cryoablation for renal tumors has been almost uniformly good, but supporters of the technique received a splash of cold water at the World Congress of Endourology here. 2006-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/432006/381348null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Laparoscopic-cryo-is-effective-in-some-cystic-rena/ArticleStandard/Article/detail/381338?contextCategoryId=9396&ref=25 Cleveland—Laparoscopic cryoablation can be used to treat cystic renal tumors in highly selected patients, according to the results of a small series from the University of Minnesota, Minneapolis. 2006-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/432006/381338null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Cryo-is-superior-to-HIFU-RFA-in-small-renal-tumors/ArticleStandard/Article/detail/381339?contextCategoryId=9396&ref=25 Cleveland—For now, laparoscopic cryoablation appears to be more effective than both radiofrequency (RF) ablation and high-intensity focused ultrasound (HIFU) in the treatment of small renal tumors, a group of Austrian researchers reported here at the 2006 World Congress of Endourology. 2006-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/432006/381339null XML http://www.modernmedicine.com/modernmedicine/Bladder%2C+Kidney%2C+and+Other+Urologic+Cancers/Cancer-surgery-choice-may-affect-kidney-disease-on/ArticleStandard/Article/detail/381347?contextCategoryId=9396&ref=25 New York—Partial nephrectomy for small renal cortical tumors, while perhaps a more challenging procedure than radical nephrectomy, significantly delays the onset of kidney disease when compared with the far more common radical procedure, according to a retrospective study from Memorial Sloan-Kettering Cancer Center, New York. 2006-10-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/432006/381347null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/African-Americans-with-bladder-cancer-have-lower-s/ArticleStandard/Article/detail/376368?contextCategoryId=9396&ref=25 African-American patients with bladder cancer are 35% more likely to die of the disease than Caucasian patients are, according to researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor. 2006-10-05T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/402006/376368null HTML